Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology DataGlobeNewsWire • 05/01/23
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor EventsGlobeNewsWire • 05/01/23
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 04/27/23
Earnings Preview: Editas Medicine (EDIT) Q1 Earnings Expected to DeclineZacks Investment Research • 04/26/23
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New DirectorGlobeNewsWire • 04/13/23
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?The Motley Fool • 04/03/23
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People OfficerGlobeNewsWire • 03/08/23
Editas: The Potential Of Gene Editing Technology And The Risks Of A Lackluster PipelineSeeking Alpha • 02/24/23
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business UpdatesGlobeNewsWire • 02/22/23
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?The Motley Fool • 02/16/23
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate UpdateGlobeNewsWire • 02/15/23